Central Nervous System Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The Business Research Company’s Central Nervous System Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, February 18, 2022 /EINPresswire.com/ -- Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics drugs manufacturers broaden their products and services. For instance, in March 2021, SEQENS and Rondol Group had announced a collaboration in formulation research and continuous flow manufacturing for existing, repurposed, or new drugs for oncology, infectious diseases, and central nervous system disorders. In June 2021, DSM and Brains Bioceutical have established a global exclusive partnership to unlock the therapeutic potential of cannabinoids in early-stage drug development. The cannabinoid API market is rapidly expanding, fueled by strong scientific evidence demonstrating cannabinoid's potential in a variety of therapeutic areas, including Central Nervous System (CNS) diseases.

According to the central nervous system drugs market overview, during the forecast period, the growth of the global central nervous system drugs market will be restrained by patent expiration of branded central nervous system drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value.

Read more on the Global Central Nervous System Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

The global central nervous system drugs market size is expected to grow from $169.11 billion in 2021 to $178.70 billion in 2022 at a compound annual growth rate (CAGR) of 5.7%. The growth in the CNS drugs market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The central nervous system drugs market is expected to reach $264.97 billion in 2026 at a CAGR of 10.3%.

North America was the largest region in the central nervous system drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the CNS drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Major players covered in the global central nervous system drugs industry are Biogen Inc, Johnson & Johnson, Novartis AG, UCB S.A., Takeda Pharmaceuticals, AbbVie, Teva Pharmaceuticals, GlaxosmithKline, Daiichi Sankyo Company and H Lundbeck.

TBRC’s global central nervous system drugs market research report is segmented by type into analgesics, anti-Parkinson drugs, anesthetics, anti-epileptics, other CNS drugs, by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a central nervous system drugs market overview, central nervous system drugs market forecast central nervous system drugs market size and growth for the whole market, central nervous system drugs market segments, geographies, central nervous system drugs market trends, central nervous system drugs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request for a Sample of the Global Central Nervous System Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2141&type=smp

Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Analgesics Global Market Report 2021 - By Type (Non-opioids, Opioids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores), By Route of Administration (Oral, Intravenous, Rectal, Transdermal, Topical), By Drug Type (Prescription Analgesics, OTC Analgesics), By Application (Internal Analgesics, External Analgesics), COVID-19 Implications And Growth
https://www.thebusinessresearchcompany.com/report/analgesics-global-market-report

Anti-Parkinson Drugs Global Market Report 2021 - By Drugs Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs). By Route of Administration (Oral, Injection, Transdermal). By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), COVID-19 Impact and Recovery
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report-2020-30-covid-19-growth-and-change

Anesthetics Global Market Report 2021 - By Type (General Anesthetics, Local Anesthetics), By Application (General Surgeries, Plastic Surgery, Cosmetic Surgeries, Dental Surgeries), By Route of Administration (Inhalation Anesthesia Drugs, Intravenous Anesthesia Drugs, Topical Anesthesia Drugs), By Local Anesthetics (Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Articaine, Benzocaine), By General Anesthetics (Propofol, Sevoflurane, Desflurane, Dexmedetomidine, Remifentanil, Midazolam), COVID-19 Implications And Growth
https://www.thebusinessresearchcompany.com/report/anesthetics-global-market-report

About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.